82 related articles for article (PubMed ID: 6937701)
1. Human plasma and amino acids as moderators of uptake and metabolic consequences of antifolates in WIL-2 and human leukemia cells.
Fyfe MJ; Sedwick WD; Brown OE; Laszlo J
J Natl Cancer Inst; 1981 Mar; 66(3):445-51. PubMed ID: 6937701
[TBL] [Abstract][Full Text] [Related]
2. New dose-time relationships of folate antagonists to sustain inhibition of human lymphoblasts and leukemic cells in vitro.
Sedwick WD; Kutler M; Frazer T; Brown OE; Laszlo J
Cancer Res; 1979 Sep; 39(9):3612-8. PubMed ID: 314333
[TBL] [Abstract][Full Text] [Related]
3. Comparison of metoprine (DDMP) and etoprine (DDEP) by measuring the inhibition of deoxyuridine incorporation into the DNA of human leukemic cells 1,2,3.
Laszlo J; Fyfe MJ; Swedwick D; Lee L; Brown O
Cancer Treat Rep; 1978 Mar; 62(3):341-4. PubMed ID: 274177
[TBL] [Abstract][Full Text] [Related]
4. Metabolic inhibition by a new antifolate, 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methyl-pyrido[2,3-d]pyrimidine (BW3O1U), an effective inhibitor of human lymphoid and dihydrofolate reductase-overproducing mouse cell lines.
Sedwick WD; Hamrell M; Brown OE; Laszlo J
Mol Pharmacol; 1982 Nov; 22(3):766-70. PubMed ID: 7155133
[TBL] [Abstract][Full Text] [Related]
5. Establishment of methotrexate-resistant human acute lymphoblastic leukemia cells in culture and effects of folate antagonists.
Ohnoshi T; Ohnuma T; Takahashi I; Scanlon K; Kamen BA; Holland JF
Cancer Res; 1982 May; 42(5):1655-60. PubMed ID: 6978176
[TBL] [Abstract][Full Text] [Related]
6. Deoxyuridine incorporation as a useful measure of methotrexate and metoprine uptake and metabolic effectiveness.
Sedwick WD; Fyfe MJ; Brown OE; Frazer TA; Kutler M; Laszlo J
Mol Pharmacol; 1979 Sep; 16(2):607-13. PubMed ID: 514260
[No Abstract] [Full Text] [Related]
7. Novel 6,5-fused ring heterocyclic antifolates: biochemical and biological characterization.
McGuire JJ; Bergoltz VV; Heitzman KJ; Haile WH; Russell CA; Bolanowska WE; Kotake Y; Haneda T; Nomura H
Cancer Res; 1994 May; 54(10):2673-9. PubMed ID: 8168096
[TBL] [Abstract][Full Text] [Related]
8. Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells.
Chen G; Wright JE; Rosowsky A
Mol Pharmacol; 1995 Oct; 48(4):758-65. PubMed ID: 7476904
[TBL] [Abstract][Full Text] [Related]
9. Crystallographic studies of the antineoplastic antifolate 2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine (DDMP) ethanesulfonate salt.
Cody V
Cancer Biochem Biophys; 1983; 6(3):173-7. PubMed ID: 6850552
[TBL] [Abstract][Full Text] [Related]
10. Combination antifol therapy: observations on the development of resistant L1210 leukemic cells in vivo.
Browman GP; Lazarus H
Cancer Treat Rep; 1980; 64(2-3):231-6. PubMed ID: 7407755
[TBL] [Abstract][Full Text] [Related]
11. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.
Barnes MJ; Estlin EJ; Taylor GA; Aherne GW; Hardcastle A; McGuire JJ; Calvete JA; Lunec J; Pearson AD; Newell DR
Clin Cancer Res; 1999 Sep; 5(9):2548-58. PubMed ID: 10499632
[TBL] [Abstract][Full Text] [Related]
12. Studies with a 2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine (DDMP)-resistant L1210 leukemia cell line without cross-resistance to methotrexate.
Browman GP; Gorka C; Mehta C; Lazarus H; Abelson HT
Biochem Pharmacol; 1980 Aug; 29(16):2241-5. PubMed ID: 7426028
[No Abstract] [Full Text] [Related]
13. Antifolate-induced misincorporation of deoxyuridine monophosphate into DNA: inhibition of high molecular weight DNA synthesis in human lymphoblastoid cells.
Sedwick WD; Kutler M; Brown OE
Proc Natl Acad Sci U S A; 1981 Feb; 78(2):917-21. PubMed ID: 6940156
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of antitumor activity of 2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine and Baker's antifol (triazinate) with carboxypeptidase G1.
Kalghatgi KK; Moroson BA; Horváth C; Bertino JR
Cancer Res; 1979 Sep; 39(9):3441-5. PubMed ID: 476673
[TBL] [Abstract][Full Text] [Related]
15. Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein.
Westerhof GR; Rijnboutt S; Schornagel JH; Pinedo HM; Peters GJ; Jansen G
Cancer Res; 1995 Sep; 55(17):3795-802. PubMed ID: 7641196
[TBL] [Abstract][Full Text] [Related]
16. 5-amino-4-imidazolecarboxamide riboside potentiates both transport of reduced folates and antifolates by the human reduced folate carrier and their subsequent metabolism.
McGuire JJ; Haile WH; Yeh CC
Cancer Res; 2006 Apr; 66(7):3836-44. PubMed ID: 16585211
[TBL] [Abstract][Full Text] [Related]
17. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
Rhee MS; Galivan J; Wright JE; Rosowsky A
Mol Pharmacol; 1994 Apr; 45(4):783-91. PubMed ID: 7514264
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells.
Mauritz R; Bekkenk MW; Rots MG; Pieters R; Mini E; van Zantwijk CH; Veerman AJ; Peters GJ; Jansen G
Clin Cancer Res; 1998 Oct; 4(10):2399-410. PubMed ID: 9796971
[TBL] [Abstract][Full Text] [Related]
19. Uptake, cytotoxicity and metabolism of m-azidopyrimethamine and related lipophilic antifolates in SV-K14 human keratinocytes in vivo.
Baker ND; Griffin RJ; Irwin WJ; Reichert U; Schmidt R
Biochem Pharmacol; 1991 Dec; 42 Suppl():S39-46. PubMed ID: 1768284
[TBL] [Abstract][Full Text] [Related]
20. Multiple mechanisms of resistance to polyglutamatable and lipophilic antifolates in mammalian cells: role of increased folylpolyglutamylation, expanded folate pools, and intralysosomal drug sequestration.
Jansen G; Barr H; Kathmann I; Bunni MA; Priest DG; Noordhuis P; Peters GJ; Assaraf YG
Mol Pharmacol; 1999 Apr; 55(4):761-9. PubMed ID: 10101035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
